Richard F Ambinder

10PUBLICATIONS
58CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunogenetics (incl. genetic immunology)Cancer therapy (excl. chemotherapy and radiation therapy)Nanotoxicology, health and safetyChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Feb 09, 2026
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.

Catherine Diefenbach, Opeyemi Jegede, Victoria Wang

|Mar 28, 2025
Prolonged Diagnostic Interval Leads to High Lymphoma Related Mortality in a Prospective Cohort of People with HIV Undergoing Fine Needle Aspiration.

Samantha L Vogt, Khuthadzo Hlongwane, Arshia Arora

|Dec 18, 2024
Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma.

Nadeem Tabbara, Marianna Zahurak, Cole H Sterling

|Feb 21, 2024
Impact of Prophylactic Trimethoprim-Sulfamethoxazole on Clearance of High-Dose Methotrexate in Adult Patients.

Daniel Skoloda, Matthew Newman, Haval Norman

|Jul 31, 2023
Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087).

Missak Haigentz, Jeannette Y Lee, Elizabeth Y Chiao

|Jul 21, 2023
Cell-Free Circulating Tumor DNA and Epstein-Barr Virus DNA for Early Diagnosis of Epstein-Barr Virus-Associated Cancers.

Rena R Xian, Richard F Ambinder

Pageof 2

Frequent Collaborators

2 joint publications

Nina Wagner-Johnston

1 joint publications

Hema Dave

1 joint publications

Keri Toner

1 joint publications

Melanie Grant